Marker Therapeutics, Inc. filings document material events, governance actions, capital-structure matters, clinical disclosures, and operating results for a clinical-stage immuno-oncology issuer. Current reports include disclosures on MAR-T cell program updates, Regulation FD materials, quarterly financial results, board appointments, and exhibits tied to company press releases and presentations.
Proxy and annual meeting materials cover director elections, advisory executive-compensation votes, auditor ratification, amendments to the certificate of incorporation, authorized common stock matters, voting-threshold provisions, and shareholder proposal procedures. These filings also record security-holder votes and related charter amendments.
Marker Therapeutics, Inc. (MRKR) was awarded a $16.2 million CPRIT Product Development Research grant to support MT-601 (neldaleucel) in the planned Phase 2 APOLLO study for patients with relapsed or refractory large B-cell lymphoma after CD19-directed CAR-T treatment. Marker described the award as non-dilutive funding. In this funding cycle, CPRIT received 207 applications and awarded $74.3 million to 12 projects.
On August 26, 2025, Marker reported a 66% objective response rate and 50% complete response rate among 12 evaluable patients with non-Hodgkin lymphoma in the Phase 1 APOLLO study. Responses lasted up to 24 months at the data cutoff. The company also reported no dose-limiting toxicities or immune-effector cell-associated neurotoxicity syndrome across evaluated dose levels. Marker said additional patient data and updated response-durability data were expected later this year.
Marker Therapeutics, Inc. (MRKR) reported a net loss of $1.84 million for the quarter ended September 30, 2026, compared with $2.00 million a year earlier; its nine-month net loss was $6.85 million versus $10.46 million. Nine-month research and development expense was $6.49 million, compared with $9.66 million in 2025, while grant income recorded as other income was $2.73 million versus $2.44 million. The company has not generated revenue from sales or licensing of its product candidates.
Cash, cash equivalents and restricted cash totaled $9.43 million at September 30, 2026. Operating activities used $7.62 million in the first nine months, compared with $10.11 million in the prior-year period. Marker estimates its resources will fund operating expenses and capital expenditures into the second quarter of 2027, assuming no additional grant funds, and states these conditions raise substantial doubt about its ability to continue as a going concern. Management is considering issuing securities and applying for grants; such funding could extend resources beyond the fourth quarter of 2027, but the company gives no assurance it will be obtained.
Marker Therapeutics, Inc. (MRKR) was awarded a $2.6 million FDA grant to support a Phase 1 clinical study of its investigational MT-601 MAR-T cell therapy in patients with locally advanced unresectable pancreatic cancer. The company anticipates clinical initiation in the first quarter of 2027.
In fiscal year 2026, the FDA selected six projects from 66 applications for its Orphan Products Clinical Trials grants program. A prior Phase 1/2 study at Baylor College of Medicine reported an 84.6% disease control rate, a median response duration of 7.5 months and median overall survival of 14.1 months in patients receiving multi-antigen targeted T cells with frontline chemotherapy.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing MAR-T cell therapies for hematologic malignancies and solid tumors. For the six months ended June 30, 2026, it reported a net loss of $5,005,507, compared with $8,461,748 a year earlier, driven mainly by lower research and development spending.
Research and development expenses fell to $4,318,888 from $7,312,481, while general and administrative expenses were relatively stable at $2,374,012. Grant income was a meaningful funding source, totaling $1,433,270 in the first half of 2026 from multiple CPRIT, FDA and NIH SBIR awards. The company also disclosed a new $4.2 million U.S. Department of War grant to support MT-601 in relapsed/refractory large B-cell lymphoma.
Cash, cash equivalents, and restricted cash were $11,922,332 as of June 30, 2026, with working capital of $12,165,464. Management expects existing cash to fund operations into the second quarter of 2027, assuming no additional grant inflows, and stated that these conditions raise substantial doubt about its ability to continue as a going concern. Marker plans to seek additional equity financing and grants while advancing its MT-401 and MT-601 programs.
Marker Therapeutics reported Q1 2026 results showing a smaller net loss while remaining pre-revenue. Net loss was $3.2 million compared with $4.4 million a year earlier, helped by lower operating expenses and higher grant income.
The company held $15.6 million in cash, cash equivalents, and restricted cash and working capital of $13.8 million as of March 31, 2026. Management expects existing resources to fund operations into the first quarter of 2027 and discloses substantial doubt about its ability to continue as a going concern without new capital or additional grant funding. The company also increased its authorized common shares from 30 million to 130 million after quarter-end.
Marker Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders. Stockholders approved a Charter Amendment to increase authorized common shares from 30,000,000 to 130,000,000. They also re-elected five directors, approved executive compensation on an advisory basis, and ratified CBIZ CPAs P.C. as auditor for the year ending December 31, 2026.
Of 16,673,127 shares outstanding as of the record date, 12,377,857 shares, or 74.24%, were represented. A separate proposal to revise the voting threshold for future changes to common stock did not pass, while an adjournment proposal related to the share increase was approved.
Marker Therapeutics is asking stockholders to vote at its May 1, 2026 virtual annual meeting on a broad set of governance and capital structure items. Stockholders will elect five directors, hold an advisory vote on executive pay, and ratify CBIZ as auditor for 2026.
A key proposal would amend the Certificate of Incorporation to increase authorized common stock from 30,000,000 to 130,000,000 shares, which could support future capital raising, equity incentives, or strategic transactions and may dilute existing holders if issued. Another proposal would lower the voting threshold for future changes to authorized share amounts or reverse splits to a majority of votes cast, aligning with recent Delaware law.
Stockholders will also vote on an adjournment proposal that would allow the meeting to be postponed to solicit more support for the share‑increase amendment if needed. The proxy describes board independence, committee structures, diversity, and compensation for President and CEO Juan Vera, M.D., who received $741,190 in total 2025 compensation.
Marker Therapeutics reported 2025 results and clinical progress for its MAR‑T cell therapies. The Phase 1 APOLLO study in relapsed non-Hodgkin lymphoma showed a 66% objective response rate, including 50% complete responses, with a favorable safety profile and dose expansion underway in DLBCL. The company plans another APOLLO data update in the second quarter of 2026 and is preparing a company-sponsored pancreatic cancer trial, supported by strong preclinical data published in Nature Medicine.
Financially, Marker ended December 31, 2025 with $17 million in cash, cash equivalents and restricted cash and expects this to fund operations through the fourth quarter of 2026. Grant revenue was $3.5 million, research and development expenses were $11.8 million, general and administrative expenses were $4.2 million, and net loss was $12.2 million, reflecting a modestly higher loss year over year as the pipeline advanced.
Marker Therapeutics files its annual report outlining progress on its MAR‑T cell immunotherapy pipeline and partnerships. The company is advancing MT‑601 for relapsed lymphoma (APOLLO trial) and pancreatic cancer (PANACEA), plus an off‑the‑shelf MT‑401 program for AML and MDS.
Grants from CPRIT and NIH/SBIR, including a $9.5 million CPRIT pancreatic cancer award and a $2 million NIH SBIR grant, are helping fund MT‑601 without diverting resources from lymphoma. Marker shifted manufacturing from Cell Ready to BCM and Cellipont to prepare for larger MT‑601 trials.
As of June 30, 2025, non‑affiliate equity market value was about $17.3 million, based on a $1.53 Nasdaq price. Shares outstanding were 16,673,127 as of March 16, 2026. The report also details extensive licensing, royalty, and regulatory frameworks around its MAR‑T platform.